Unacylated Ghrelin Protects Against Age-Related Loss of Muscle Mass and Contractile Dysfunction in Skeletal Muscle
- PMID: 39223708
- PMCID: PMC11634730
- DOI: 10.1111/acel.14323
Unacylated Ghrelin Protects Against Age-Related Loss of Muscle Mass and Contractile Dysfunction in Skeletal Muscle
Abstract
Sarcopenia, the progressive loss of muscle mass and function, universally affects older adults and is closely associated with frailty and reduced quality of life. Despite the inevitable consequences of sarcopenia and its relevance to healthspan, no pharmacological therapies are currently available. Ghrelin is a gut-released hormone that increases appetite and body weight through acylation. Acylated ghrelin activates its receptor, growth hormone secretagogue receptor 1a (GHSR1a), in the brain by binding to it. Studies have demonstrated that acyl and unacylated ghrelin (UnAG) both have protective effects against acute pathological conditions independent of receptor activation. Here, we investigated the long-term effects of UnAG in age-associated muscle atrophy and contractile dysfunction in mice. Four-month-old and 18-month-old mice were subjected to either UnAG or control treatment for 10 months. UnAG did not affect food consumption or body weight. Gastrocnemius and quadriceps muscle weights were reduced by 20%-30% with age, which was partially protected against by UnAG. Specific force, force per cross-sectional area, measured in isolated extensor digitorum longus muscle was diminished by 30% in old mice; however, UnAG prevented the loss of specific force. UnAG also protected from decreases in mitochondrial respiration and increases in hydrogen peroxide generation of skeletal muscle of old mice. Results of bulk mRNA-seq analysis and our contractile function data show that UnAG reversed neuromuscular junction impairment that occurs with age. Collectively, our data revealed the direct role of UnAG in mitigating sarcopenia in mice, independent of food consumption or body weight, implicating UnAG treatment as a potential therapy against sarcopenia.
Keywords: loss of muscle mass; mitochondria; neurogenic atrophy; neuromuscular junction; protein synthesis and degradation; sarcopenia; unacylated ghrelin.
© 2024 The Author(s). Aging Cell published by Anatomical Society and John Wiley & Sons Ltd.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures
References
-
- Agosti, E. , De Feudis, M. , Angelino, E. , Bellis, R. , Teixeira, M. A. , Zaggia, I. , Tamiso, E. , Raiteri, T. , Scircoli, A. , Ronzoni, F. L. , Muscaritoli, M. , Graziani, A. , Prodam, F. , Sampaolesi, M. , Costelli, P. , Ferraro, E. , ReanoL, S. , & Filigheddu, N. (2020). Both ghrelin deletion and unacylated ghrelin overexpression preserve muscles in aging mice. Aging, 12(14), 13939–13957. 10.18632/aging.103802 - DOI - PMC - PubMed
-
- Ahn, B. , Pharaoh, G. , Premkumar, P. , Huseman, K. , Ranjit, R. , Kinter, M. , Szweda, L. , Kiss, T. , Fulop, G. , Tarantini, S. , Csiszar, A. , Ungvari, Z. , & Van Remmen, H. (2018). Nrf2 deficiency exacerbates age‐related contractile dysfunction and loss of skeletal muscle mass. Redox Biology, 17, 47–58. 10.1016/j.redox.2018.04.004 - DOI - PMC - PubMed
-
- Ahn, B. , Ranjit, R. , Kneis, P. , Xu, H. , Piekarz, K. M. , Freeman, W. M. , Kinter, M. , Richardson, A. , Ran, Q. , Brooks, S. V. , & Van Remmen, H. (2022). Scavenging mitochondrial hydrogen peroxide by peroxiredoxin 3 overexpression attenuates contractile dysfunction and muscle atrophy in a murine model of accelerated sarcopenia. Aging Cell, 21(3), e13569. 10.1111/acel.13569 - DOI - PMC - PubMed
-
- Ahn, B. , Ranjit, R. , Premkumar, P. , Pharaoh, G. , Piekarz, K. M. , Matsuzaki, S. , Claflin, D. R. , Riddle, K. , Judge, J. , Bhaskaran, S. , Satara Natarajan, K. , Barboza, E. , Wronowski, B. , Kinter, M. , Humphries, K. M. , Griffin, T. M. , Freeman, W. M. , Richardson, A. , Brooks, S. V. , & Van Remmen, H. (2019). Mitochondrial oxidative stress impairs contractile function but paradoxically increases muscle mass via fibre branching. Journal of Cachexia, Sarcopenia and Muscle, 10(5), 1148. 10.1002/jcsm.12493 - DOI - PMC - PubMed
-
- Allas, S. , Caixàs, A. , Poitou, C. , Coupaye, M. , Thuilleaux, D. , Lorenzini, F. , Diene, G. , Crinò, A. , Illouz, F. , Grugni, G. , Potvin, D. , Bocchini, S. , Delale, T. , Abribat, T. , & Tauber, M. (2018). AZP‐531, an unacylated ghrelin analog, improves food‐related behavior in patients with Prader–Willi syndrome: A randomized placebo‐controlled trial. PLoS One, 13(1), e0190849. 10.1371/journal.pone.0190849 - DOI - PMC - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
